EU-kommissionen bidrar med motsvarande 3,5 miljarder svenska kronor till fem projekt för gemensam upphandling av ...
Latourägda batteriladdarbolaget CTEK rapporterar stigande intäkter i tredje kvartalet, samt ökad lönsamhet. Intäkterna från ...
Minna Technologies är baserat i Göteborg och omsatte 34 miljoner kronor under 2023 ... Affären kommer för första gången ge Schweizhs största … Novo Nordisk förvärvar kanadensiskt bolag Novo Nordisk ...
Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, whose profits from blockbuster weight-loss ...
Eli Lilly and Novo Nordisk didn't quite beat expectations with their recent earnings. Their weight loss drugs slightly underperformed. That underperformance may portend more difficulty.
Efter transaktionen äger Novo Holdings cirka 1,07 miljoner A-aktier och 177,6 miljoner B-aktier, motsvarande 28,1 procent av kapitalet och 77,3 procent av rösterna i Novo Nordisk.
After massive market cap growth for Eli Lilly and Novo Nordisk since the start of the decade, investor enthusiasm dimmed for the two most valuable companies in the industry in the third quarter.
Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...
1 Day NVO 1.88% DJIA 0.68% S&P 500 -0.03% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...